Revolution Medicines Reaffirms 2026 GAAP Operating Expense Guidance Following RASONQUE FDA Approval
Revolution Medicines (RVMD) has reiterated its 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion. This reaffirmation follows a significant milestone for the company: the FDA approval of its product, RASONQUE, which occurred on August 26. The company transitioned immediately into the commercial phase by making RASONQUE available by prescription in the United States. Management characterized the third quarter as a transformational period for the organization as it moves from development toward active market presence.
Tickers: $RVMD
Topics: Biotechnology Earnings Call FDA Approval Product Launch
Read the full article at Seeking Alpha
Part of the story Vera Therapeutics Reports Q3 2026 Results Following TRUTAKNA Commercial Launch (9 articles)